Henry Schein INC: management transactions · United States · SEC (Form 4)

About Henry Schein INC

Henry Schein Inc. is a leading provider of healthcare solutions for office-based dental and medical practitioners. The company is listed on the U.S. market, NASDAQ (United States), was founded in 1932, and is headquartered in Melville, New York. What began as a dental-focused distributor has evolved into a broader healthcare platform spanning consumables, equipment, specialty products, software, and value-added services for clinicians and practice owners. The business is now organized around three core segments. First, Global Distribution and Value-Added Services covers the sale of branded and private-label merchandise, equipment, technical services, and advisory offerings such as practice transition, consulting, continuing education, and financial services. Second, Global Specialty Products includes manufacturing, marketing, and sales of dental implant and biomaterial products, as well as endodontic, orthodontic, orthopedic, and other healthcare-related products. Third, Global Technology comprises practice management software, e-services, and related digital solutions. This mix of distribution, proprietary products, and software creates a diversified model with recurring demand characteristics and a broad customer base. From a competitive standpoint, Henry Schein holds a strong position in the dental and medical office supply chain, supported by its scale, logistics footprint, technical service capabilities, and integrated offering. The company operates in 33 countries and territories, giving it meaningful international reach beyond its U.S. home market. Its competitive advantages are particularly visible in relationships with independent practitioners, where product availability, service quality, software integration, and equipment support matter as much as price. At the same time, the company faces intense competition from specialty distributors, manufacturers, and online commerce platforms. Recent developments are important for investors. In January 2025, Henry Schein announced a strategic investment by KKR, board changes, and a value-creation collaboration framework. The company also updated its reportable segment structure in 2025 to better align external reporting with management’s internal view of the business. Operationally, 2025 results highlighted growth in medical distribution, specialty products, and technology, supported by underlying demand from dental and physician offices, acquisitions, and expanding cloud-based software offerings such as Dentrix Ascend and Dentally. For international equity investors, HSIC represents a mature U.S. healthcare franchise with global exposure, a resilient end-market, and an evolving mix of distribution, specialty manufacturing, and digital workflow solutions.